IDH1 and glioblastoma: On the other hand, when glioma was histologically sub-grouped to analyze the impact of chemotherapy using TMZ, GBM showed significantly better survival in both wild-type groups of IDH1 (13.0 vs 27.5 months; log-rank p = 0.03; Figure 2A) and IDH 2 (23.8 vs 11.7 months; log-rank p = 0.04; Figure 2B) as compared with mutants (10.0–17.0 months for IDH1; Figure 2C).